113 related articles for article (PubMed ID: 1781182)
1. Study of the skin concentrations after administration of the various phototoxic drugs.
Park YK; Hann SK; Cho MY; Kim HJ; Shim SC; Choi SJ; Yun MH
Yonsei Med J; 1991 Sep; 32(3):231-6. PubMed ID: 1781182
[TBL] [Abstract][Full Text] [Related]
2. Skin concentration of 8-methoxypsoralen, 5-methoxypsoralen and 4,5,8-trimethylpsoralen in guinea pigs.
Park YK; Hann SK; Im S; Kim S
J Dermatol Sci; 1993 Feb; 5(1):19-24. PubMed ID: 8485109
[TBL] [Abstract][Full Text] [Related]
3. Bath PUVA--an investigation of the distribution of trioxsalen (TMP) and 8-methoxypsoralen (8-MOP) in bathwater.
Wainwright NJ; MacLeod TM; Ferguson J
Photodermatol Photoimmunol Photomed; 1997; 13(1-2):17-20. PubMed ID: 9361123
[TBL] [Abstract][Full Text] [Related]
4. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
Man I; McKinlay J; Dawe RS; Ferguson J; Ibbotson SH
J Am Acad Dermatol; 2003 Jul; 49(1):59-64. PubMed ID: 12833009
[TBL] [Abstract][Full Text] [Related]
5. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
Shephard SE; Panizzon RG
Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
[TBL] [Abstract][Full Text] [Related]
6. The effect of PUVA on langerhans cells in rat oral epithelium photosensitized with systemic methoxsalen or topical trioxsalen.
Kuusilehto A; Happonen RP; Peltola J; Lehtinen R; Jansén CT
Photodermatol Photoimmunol Photomed; 2000 Jun; 16(3):129-33. PubMed ID: 10885443
[TBL] [Abstract][Full Text] [Related]
7. Determination of trimethylpsoralen in blood, ophthalmic fluids, and skin.
Chakrabarti SG; Grimes PE; Minus HR; Kenney JA; Pradhan TK
J Invest Dermatol; 1982 Dec; 79(6):374-7. PubMed ID: 7142738
[TBL] [Abstract][Full Text] [Related]
8. The effect of UVA irradiation on the epidermal melanocyte after 8-MOP and TMP administration.
Park YK; Hann SK; Cho MY; Hahn CS; Kim HJ; Hong KT
J Dermatol Sci; 1990 Sep; 1(5):355-9. PubMed ID: 2127374
[TBL] [Abstract][Full Text] [Related]
9. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment.
Tanew A; Kipfelsperger T; Seeber A; Radakovic-Fijan S; Hönigsmann H
J Am Acad Dermatol; 2001 Apr; 44(4):638-42. PubMed ID: 11260539
[TBL] [Abstract][Full Text] [Related]
10. Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.
Grundmann-Kollmann M; Podda M; Bräutigam L; Hardt-Weinelt K; Ludwig RJ; Geisslinger G; Kaufmann R; Tegeder I
Br J Clin Pharmacol; 2002 Nov; 54(5):535-9. PubMed ID: 12445034
[TBL] [Abstract][Full Text] [Related]
11. Difference in topical and systemic reactivity of psoralens: determinations of epidermal and serum levels.
Kornhauser A; Wamer WG; Giles AL
Natl Cancer Inst Monogr; 1984 Dec; 66():97-101. PubMed ID: 6531046
[TBL] [Abstract][Full Text] [Related]
12. Psoralen phototoxicity: correlation with serum and epidermal 8-methoxypsoralen and 5-methoxypsoralen in the guinea pig.
Kornhauser A; Wamer WG; Giles AL
Science; 1982 Aug; 217(4561):733-5. PubMed ID: 7100920
[TBL] [Abstract][Full Text] [Related]
13. Skin photosensitizing and Langerhans' cell depleting activity of topical (bath) PUVA therapy: comparison of trimethylpsoralen and 8-methoxypsoralen.
Koulu L; Jansén CT
Acta Derm Venereol; 1983; 63(2):137-41. PubMed ID: 6189328
[TBL] [Abstract][Full Text] [Related]
14. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.
Tegeder I; Bräutigam L; Podda M; Meier S; Kaufmann R; Geisslinger G; Grundmann-Kollmann M
Clin Pharmacol Ther; 2002 Mar; 71(3):153-61. PubMed ID: 11907489
[TBL] [Abstract][Full Text] [Related]
15. Skin pigmentation as a predictor of minimal phototoxic dose after oral methoxsalen.
Bech-Thomsen N; Angelo HR; Wulf HC
Arch Dermatol; 1994 Apr; 130(4):464-8. PubMed ID: 8166483
[TBL] [Abstract][Full Text] [Related]
16. A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema.
De Rie MA; Van Eendenburg JP; Versnick AC; Stolk LM; Bos JD; Westerhof W
Br J Dermatol; 1995 Jun; 132(6):964-9. PubMed ID: 7662576
[TBL] [Abstract][Full Text] [Related]
17. The effect of psoralens on hepatic and cutaneous drug metabolizing enzymes and cytochrome P-450.
Bickers DR; Mukhtar H; Molica SJ; Pathak MA
J Invest Dermatol; 1982 Sep; 79(3):201-5. PubMed ID: 7108267
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report.
Lindelöf B; Sigurgeirsson B; Tegner E; Larkö O; Berne B
Arch Dermatol; 1992 Oct; 128(10):1341-4. PubMed ID: 1417020
[TBL] [Abstract][Full Text] [Related]
19. The carcinogenic properties of topical PUVA. A lifelong study in mice.
Hannuksela M; Stenbäck F; Lahti A
Arch Dermatol Res; 1986; 278(5):347-51. PubMed ID: 3753032
[TBL] [Abstract][Full Text] [Related]
20. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides.
Weber F; Schmuth M; Sepp N; Fritsch P
Acta Derm Venereol; 2005; 85(4):329-32. PubMed ID: 16191854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
